Denali Therapeutics down after its ALS drug fails in mid-to-late stage trial

Denali Therapeutics

06/01/2025 22:04

** Shares of Denali Therapeutics Inc  DNLI.O  down 7.6% at $18.30 in after-hours trading
    ** DNLI's experimental drug fails to meet the main goal of a mid-to-late stage trial in
patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease
    ** The study did not meet the primary endpoint of efficacy in slowing disease progression as
compared with a placebo
    ** Company's medical chief Carole Ho says a more comprehensive analysis of the study results
will be available later this year
    ** "We remain deeply committed to fully understanding the effects of DNL343 in ALS and will
further evaluate the data before determining next steps" — Merit Cudkowicz, study's principal
investigator
    

 (Reporting by Juby Babu in Mexico City)
 ((Juby.Babu@thomsonreuters.com))